Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 2 Details of irAEs that occurred among the patients

From: Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors

Grade of irAEs

Number of patients (%)

Grade 1

87 (20.8%)

Grade 2

75 (17.9%)

Grade 3

7 (1.7%)

Grade 4

7 (1.7%)

IrAEs category

 

Pneumonia

38 (9.1%)

Thyroiditis, hypothyroidism, hyperthyroidism

38 (9.1%)

Cardiovascular toxicity

34 (8.1%)

Dermatologic toxicity

29 (6.9%)

Hepatitis

17 (4.1%)

Diarrhea, colitis

5 (1.2%)

Hyponatremia

3 (0.7%)

Oral mucositis

2 (0.5%)

Adrenal insufficiency

2 (0.5%)

Nephritis

2 (0.5%)

Diabetes mellitus

2 (0.5%)

Encephalitis

1 (0.2%)

Myathenia gravis

1 (0.2%)

Hemolysis

1 (0.2%)

Hypopituitarism

1 (0.2%)

Total patients irAEs

176 (42.1%)